NTP
This article was originally published in The Rose Sheet
Executive Summary
Di(2-ethylhexyl) phthalate monograph will be released in October by National Toxicology Program's Center for the Evaluation of Risks to Human Reproduction, agency reports during Board of Scientific Counselors Meeting Sept. 10-11 in Research Triangle Park, N.C. NTP released a monograph on di-n-butyl phthalate in March (1"The Rose Sheet" March 24, 2003, p. 6). Agency also unveiled its draft vision for the toxicology program, which advocates shifting basis for decision-making to rely on faster, mechanism-based assays rather than empirical tests. NTP anticipates developing more specific draft principles, roadmap of goals to be accomplished under new strategy by July 2004...
You may also be interested in...
Di-N-Butyl Phthalate Monograph Released By NTP
The National Toxicology Program has "some concern" di-n-butyl phthalate causes adverse effects to human development, particularly development of the reproductive system, according to a monograph released by NTP's Center for the Evaluation of Risks to Human Reproduction in a 1March 18 Federal Register notice
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.